Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 26S proteasome is a massive multi-subunit protease complex essential for maintaining cellular protein homeostasis by degrading misfolded or short-lived proteins tagged with ubiquitin (UniProt P28072, Q99436). The 20S core particle serves as the catalytic engine of this complex, containing three pairs of active sites: the beta 1 (PSMB6) subunit providing caspase-like activity, the beta 2 (PSMB7) subunit providing trypsin-like activity, and the beta 5 subunit providing chymotrypsin-like activity (PubMed: 26151217). These subunits utilize a unique N-terminal threonine residue to perform peptide bond hydrolysis. In hematological malignancies like multiple myeloma, cells are highly dependent on proteasome activity to manage the high volume of immunoglobulin production; thus, inhibiting these subunits leads to the accumulation of toxic protein aggregates, endoplasmic reticulum stress, and programmed cell death (StatPearls: NBK542311). While many clinical proteasome inhibitors primarily target the beta 5 subunit, secondary inhibition of the beta 1 and beta 2 subunits is often required to achieve maximal therapeutic efficacy and overcome drug resistance (PubMed: 21112705).
Inhibition of the catalytic N-terminal threonine residue within the beta subunits of the 20S core, preventing the degradation of polyubiquitinated proteins and inducing proteotoxic stress and apoptosis.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 26S proteasome 20S core subunit beta 1 and beta 2 (PSMB6 and PSMB7).